Compare Enact Holdings Inc (ACT) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Ascendis Pharma A/S — how do they compare? Enact Holdings Inc trades at $44.96 (market cap $6.35B), while Ascendis Pharma A/S trades at $277.16 (market cap $17.51B). The key difference: Ascendis Pharma A/S is far larger — about 2.8× Enact Holdings Inc's market cap, and Enact Holdings Inc pays a 1.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ACT | ASND | |
|---|---|---|
Market Cap | $6.35B | $17.51B |
Sector | Technology | Health |
52-Week High | $45.71 | $274.50 |
52-Week Low | $34.39 | $163.32 |
Enterprise Value | $6.55B | $17.88B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
